Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases
Nano Letters · 2025
DOI: 10.1021/acs.nanolett.5c03184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2025. Verfasst von Hongyu Ren und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China. Hauptthemen laut MEDLINE: Nanoparticles, Liver, RNA, Messenger, Lipids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Beijing Natural Science Foundation, Key Technology Program for Cell and Gene Therapy of NCTIB.
Abstract (Originalsprache)
An optimal administration approach is critical for effective mRNA delivery and treatment. Nebulizer inhalation offers a mild, convenient, and noninvasive strategy with high translational potential but primarily focused on lung delivery. In this study, we found that surface charges influence tissue targeting of mRNA lipid nanoparticle (mRNA-LNP) postnebulization. Charged mRNA-LNPs showed lung tropism, while neutral ones targeted the liver when administered via a microsprayer aerosolizer. Using nebulized liver-targeted LNPs (NebuLi LNPs), we successfully delivered therapeutic mRNAs for the treatment of metabolic diseases. In a Hereditary Tyrosinemia Type 1 model, fumarylacetoacetate hydrolase mRNA was effectively delivered to the liver, which helped to maintain mouse body weight, preserve liver function, and delay liver fibrosis. In a Type 2 diabetes model, dulaglutide mRNA was effectively expressed in the liver and exhibited good hypoglycemic effects. Overall, the NebuLi LNPs delivery platform offers a promising noninvasive strategy for metabolic disease treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
- Beijing Institute for Stem Cell and Regenerative Medicine, Beijing 100101, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Department of Biomedical Engineering, College of Future Technology, Beijing Advanced Center of RNA Biology (BEACON), Peking University, Beijing 100871, China.
- Beijing Life Science Academy, Yingcai South First Street, Changping District, Beijing 102200, China.
ORCID-Profile: Qiang Cheng, Tuo Wei
Förderung
- National Key Research and Development Program of China
- Beijing Natural Science Foundation
- Key Technology Program for Cell and Gene Therapy of NCTIB
- Project from Beijing Institute for Stem Cell and Regenerative Medicine
- Chinese Academy of Sciences
- Natural Science Foundation of Beijing Municipality
- fund from the Key Laboratory of Organ Regeneration and Reconstruction, Chinese Academy of Sciences
- the Open Research Fund of Beijing Advanced Center of RNA Biology (BEACON) at Peking University
Zitieren
APA
Ren, H., Yu, X., Li, M., Luo, Z., Lin, Y., Meng, Y., Cheng, Q., & Wei, T. (2025). Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c03184
Vancouver
Ren H, Yu X, Li M, Luo Z, Lin Y, Meng Y, et al. Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases. Nano Letters. 2025. doi:10.1021/acs.nanolett.5c03184
BibTeX
@article{Ren2025,
author = {Ren, Hongyu and Yu, Xiaolu and Li, Mengyao and Luo, Zijin and Lin, Yi and Meng, Yanan and Cheng, Qiang and Wei, Tuo},
title = {Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases},
journal = {Nano Letters},
year = {2025},
doi = {10.1021/acs.nanolett.5c03184}
}
EUVIMED